SCHEMBL4970562

SCHEMBL4970562

O=C(Nc1ccccc1)c1cc(=O)c2ccccc2o1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.82
MAOA P21397 2/20 0.82
KMT2A Q03164 7/20 0.80
MEN1 O00255 6/20 0.80
NPC1 O15118 4/20 0.80
RAB9A P51151 4/20 0.80
MAPT P10636 3/20 0.80
SMN1; SMN2 Q16637 3/20 0.80
POLB P06746 2/20 0.80
HTT P42858 1/20 0.80
ALDH1A1 P00352 2/20 0.75
RXFP1 Q9HBX9 1/20 0.74
LMNA P02545 1/20 0.68
KDM4E B2RXH2 1/20 0.67
USP2 O75604 1/20 0.67
CSNK2A2 P19784 1/20 0.67
PTGS1 P23219 1/20 0.67
CSNK2B P67870 1/20 0.67
CSNK2A1 P68400 1/20 0.67
CSNK2A3 Q8NEV1 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4971130 0.90 MAOB (1.00) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL30643076 0.88 RXFP1 (0.82) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL29923932 0.86 KMT2A (0.81) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL28926782 0.86 KMT2A (0.81) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL5826076 0.85 KMT2A (0.75) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL12501713 0.85 KMT2A (0.78) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL4970371 0.85 MAOB (1.00) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL8642632 0.84 MAOA (0.71) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL8647533 0.82 KMT2A (0.70) MAOBMAOAKMT2AMEN1NPC1
SCHEMBL8645195 0.81 LMNA (0.67) MAOBMAOAKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008104925-A1 CHROMONE DERIVATIVES FOR USE AS ANTIOXIDANTS/PRESERVATIVES UNIVERSIDADE DO PORTO (PT) 2008-09-04 WO claimed
CN-109641864-B Anti-infective agents 邓迪大学 2023-04-04 CN disclosed
US-10391070-B2 Compositions and methods for treating neurological diseases or injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-27 US disclosed
US-10391070-B2 Compositions and methods for treating neurological diseases or injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2019-08-27 US disclosed
US-20180185306-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-07-05 US disclosed
US-20180185306-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-07-05 US disclosed
US-9861596-B2 Compositions and methods for treating neurological diseases or injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-01-09 US disclosed
US-20150320702-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MEDICAL UNIVERSITY OF SOUTH CAROLINA 2015-11-12 US disclosed
US-20150320702-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MEDICAL UNIVERSITY OF SOUTH CAROLINA 2015-11-12 US disclosed
WO-2014074976-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-05-15 WO disclosed
WO-2014074976-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-05-15 WO disclosed
WO-2008104925-A1 CHROMONE DERIVATIVES FOR USE AS ANTIOXIDANTS/PRESERVATIVES UNIVERSIDADE DO PORTO (PT) 2008-09-04 WO disclosed
EP-0787723-B1 CYCLOPROPACHROMENECARBOXYLATE DERIVATIVES SUNTORY LTD (JP) 2003-01-15 EP disclosed
US-5843988-A Cyclopropachromencarboxylic acid derivatives SUNTORY LIMITED (JP) 1998-12-01 US disclosed
EP-0787723-A1 CYCLOPROPACHROMENECARBOXYLATE DERIVATIVES SUNTORY LIMITED (JP) 1997-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391070-B2 Compositions and methods for treating neurological diseases or injury PROC, GLS, NLN MAOB 1041/4885MAOA 1292/4885KMT2A 1760/4885
US-20150320702-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY PROC, GLS, NLN MAOB 1041/4885MAOA 1292/4885KMT2A 1760/4885
US-20180185306-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY PROC, GLS, NLN MAOB 1041/4885MAOA 1292/4885KMT2A 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.